Case Summary:

“[The client] is a leading influence in vaccine development whose work has contributed to the emerging field of nano vaccines. [Client’s] research has improved the accessibility of nano vaccines by streamlining their manufacturing and providing an approach to producing these effective molecules through self-assembly in vivo. [Client’s] research is, therefore, invaluable to global efforts to improve the treatment of human diseases.”

“[The client] has undoubtedly made important additions to her field, which also promote the national interests of the United States. [The client] is an innovative researcher working precisely in this domain. Employing her unsurpassed expertise in immunology, she has developed standard protocols to evaluate the safety and effectiveness of inoculations. As her insightful research assessing the viability of vaccine candidates for SARS-CoV2 illustrates, [the client’s] assays fill a substantial need for advancing interventions for infectious disease, enabling researchers to explore an array of therapeutic agents and isolate the most effective options.”

These are two excerpts taken from the letters of recommendation that our EB1-A (Alien of Extraordinary Ability) client from India obtained at our behest. She is a research assistant IV in immunology with an M.S. degree in biological sciences. She is one of the few leading vaccine development experts in the area, and she has achieved a consistent and notable record of success as well. She is especially well-known for her work on functional immunoglobulin G detection. Additionally, her work has influenced the research of hundreds of her peers in the field, both in the United States and around the world.

The field has recognized her authority by inviting her to review and evaluate the work of her peers no fewer than 16 times. She has also actively engaged her peers in the field of immunology by authoring and co-authoring 9 peer-reviewed articles that have been published in international journals. Furthermore, her overall work related to functional immunoglobulin G detection, development of DNA vaccine candidates for various infectious diseases including COVID-19, etc. has been cited 620 times. This makes her one of the top 1% most highly cited authors publishing on topics in DNA vaccination over the past 3 years according to Microsoft Academic. Additionally, data procured from Google Scholar shows that these publications have been cited by researchers in at least 41 countries. Our team was also able to find evidence of her major funding source namely the Coalition for Epidemic Preparedness Innovations.

Thus it was evident to us as we made clear to the adjudication bench at USCIS too, that not only has our client shown that she meets at least three of the regulatory criteria, but the evidence in the aggregate also demonstrates her national and international acclaim and position at the very top of her field.

So thanks to Premium Processing and our team effort, when we received her EB1-A approval just 7 days after her filing, we were very happy to hear of it. We are glad to have had the opportunity to help her in this process and we wish her the best in life.